China's National Medical Products Administration accepted the marketing application of Beijing Aosaikang Pharmaceutical's (SHE:002755) unit, Jiangsu Aosaikang Pharmaceutical, for isavuconazole sulfate capsules, according to a Shenzhen Stock Exchange disclosure on Monday.
The drug is used to treat adults infected with invasive aspergillosis and invasive mucormycosis, the pharmaceutical company said.
The company's shares fell less than 4% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments